The global cell therapy industry continues to rise during the second and third quarters of 2012.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 23217418.
- Also identified by DOI 10.1016/j.stem.2012.11.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.
Medical subject headings
- Cell- and Tissue-Based Therapy
- Drug Industry
- Internationality